Donald B. Smith, Jens Bukh, Carla Kuiken, A. Scott Muerhoff, Charles M. Rice, Jack T. Stapleton, Peter Simmonds – 1 October 2013 – The 2005 consensus proposal for the classification of hepatitis C virus (HCV) presented an agreed and uniform nomenclature for HCV variants and the criteria for their assignment into genotypes and subtypes. Since its publication, the available dataset of HCV sequences has vastly expanded through advancement in nucleotide sequencing technologies and an increasing focus on the role of HCV genetic variation in disease and treatment outcomes.

1 October 2013

Alberto Sanchez‐Fueyo – 23 September 2013

Adalbert Krawczyk, Hedwig Roggendorf, Charlotte Ludwig, Kerstin Herzer, Guido Gerken, Peter A. Horn, Michael Roggendorf, Monika Lindemann – 23 September 2013

Sanjiv Saigal, Narendra S. Choudhary, Neeraj Saraf, Sushila Kataria, Ravi Mohanka, Arvinder S. Soin – 23 September 2013

Michel Blé, Victoria Aguilera, Angel Rubín, María García‐Eliz, Carmen Vinaixa, Martín Prieto, Marina Berenguer – 23 September 2013 – Hepatitis C virus (HCV) is associated with renal complications. We aimed to determine whether a sustained virological response (SVR) was associated with improvements in renal function (RF) in liver transplant (LT) recipients treated for HCV. Changes in RF were compared 1, 3, and 5 years after therapy as a function of the stage of chronic kidney disease (CKD) before treatment (BT).

Henry C. Lin, Luis Alvarez, Greggy Laroche, Hector Melin‐Aldana, Kim Pfeifer, Kathleen Schwarz, Peter F. Whitington, Estella M. Alonso, Udeme D. Ekong – 23 September 2013 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) results from recessive mutations in the adenosine triphosphate–binding cassette B11 gene, which encodes for bile salt export pump (BSEP). Liver transplantation (LT) is offered to PFIC2 patients with end‐stage liver disease.

James F. Trotter – 23 September 2013

Neil Mehta, Jennifer L. Dodge, Aparna Goel, John Paul Roberts, Ryutaro Hirose, Francis Y. Yao – 23 September 2013 – It has been shown that patients with hepatocellular carcinoma (HCC) meeting the United Network for Organ Sharing T2 (Milan) criteria have an advantage in comparison with patients without HCC under the current organ allocation system for liver transplantation (LT). We hypothesized that within the T2 HCC group, there is a subgroup with a low risk of wait‐list dropout that should not receive the same listing priority.

Robert W. Krell, Daniel R. Kaul, Andrew R. Martin, Michael J. Englesbe, Christopher J. Sonnenday, Shijie Cai, Preeti N. Malani – 23 September 2013 – Although sarcopenia (muscle loss) is associated with increased mortality after liver transplantation, its influence on other complications is less well understood. We examined the association between sarcopenia and the risk of severe posttransplant infections among adult liver transplant recipients. By calculating the total psoas area (TPA) on preoperative computed tomography scans, we assessed sarcopenia among 207 liver transplant recipients.